GlassScriptPhysician profile
Huma Parveen Ahmed
NPI 1972616241
$7,857.10
in general payments reported to CMS, 2019-2025
29 companies · $1,233 in 2025
The $1,233 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $592 · 2020: $323 · 2021: $1,044 · 2022: $1,366 · 2023: $1,655 · 2024: $1,644 · 2025: $1,233.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,233 · Education: $299.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,233.09 |
| Education | $298.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,115.14 | 2019-2025 | Enbrel, Otezla, Krystexxa |
| Abbvie INC. | $1,203.42 | 2019-2025 | Rinvoq, Skyrizi |
| Ucb, INC. | $722.26 | 2019-2025 | Cimzia, Bimzelx |
| Janssen Biotech, INC. | $714.05 | 2020-2025 | Tremfya, Simponi Aria |
| Pfizer INC. | $631.03 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $368.07 | 2019-2025 | Ofev, Cyltezo |
| Horizon Therapeutics Plc | $320.34 | 2019-2023 | Krystexxa |
| Glaxosmithkline, LLC. | $300.25 | 2021-2025 | Benlysta |
| Mallinckrodt Hospital Products INC. | $289.06 | 2021-2025 | Acthar |
| Novartis Pharmaceuticals Corporation | $270.87 | 2019-2024 | |
| Lilly USA, LLC | $256.71 | 2021-2025 | Taltz, Olumiant |
| Aurinia Pharma U.S., INC. | $96.85 | 2021-2025 | Lupkynis |
| Ani Pharmaceuticals, INC. | $68.18 | 2025 | Purified Cortrophin Gel |
| Bayer Healthcare Pharmaceuticals INC. | $63.39 | 2019-2024 | |
| Radius Health, INC. | $58.29 | 2023 | Tymlos |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius Kabi USA, LLC | $51.43 | 2023-2024 | Idacio |
| Alexion Pharmaceuticals, INC. | $42.53 | 2022-2025 | Strensiq |
| E.R. Squibb & Sons, L.L.C. | $38.15 | 2021 | |
| Genzyme Corporation | $37.16 | 2019 | |
| Csl Behring | $30.82 | 2025 | Hizentra |
| Scilex Pharmaceuticals INC. | $28.80 | 2024 | |
| Tonix Medicines, INC. | $24.45 | 2025 | Tonmya |
| Eisai INC. | $21.45 | 2024 | |
| Sobi, INC | $21.26 | 2025 | |
| Fidia Pharma USA INC. | $20.34 | 2019-2020 | |
| Organon LLC | $20.14 | 2023 | Hadlima, Renflexis |
| Mallinckrodt Enterprises LLC | $15.30 | 2019 | |
| Genentech USA, INC. | $15.19 | 2024 | Actemra |
| Currax Pharmaceuticals LLC | $12.17 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Huma Ahmed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.